- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Royalty Pharma Plc (RPRX)
Royalty Pharma Plc stock price live, this page displays NASDAQ RPRX stock exchange data. View the RPRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Royalty Pharma Plc real time stock price chart below.
What Is the Royalty Pharma Plc Stock Price Today?
The Royalty Pharma Plc stock price today is 49.55.
What Is the Stock Symbol for Royalty Pharma Plc?
The stock symbol for Royalty Pharma Plc is "RPRX."
What Stock Exchange Does Royalty Pharma Plc Trade On?
Royalty Pharma Plc is listed and trades on the NASDAQ stock exchange.
Is Royalty Pharma Plc a Good Stock to Buy?
Determining whether Royalty Pharma Plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RPRX quote. (ISIN: GB00BMVP7Y09)
What Is the Royalty Pharma Plc Stock Price Today?
The Royalty Pharma Plc stock price today is 49.55.
What Is the Stock Symbol for Royalty Pharma Plc?
The stock symbol for Royalty Pharma Plc is "RPRX."
What Stock Exchange Does Royalty Pharma Plc Trade On?
Royalty Pharma Plc is listed and trades on the NASDAQ stock exchange.
Is Royalty Pharma Plc a Good Stock to Buy?
Determining whether Royalty Pharma Plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RPRX quote. (ISIN: GB00BMVP7Y09)
49.55
-0.09(-0.18%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
49.20
49.64
52 wk Range
31.84
50.08
Earnings results expected in 12 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
49.2049.64
52 wk Range
31.8450.08
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.89%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.89%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RPRX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
52.44
Upside
+5.84%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 6 consecutive years
- Form 144 Royalty Pharma plc For: 1 April
- Investing.com
- Royalty Pharma stock hits 52-week high at $49.07
- Investing.com
- Royalty Pharma stock hits 52-week high at $49.07
- Investing.com
- Royalty Pharma declares $0.235 quarterly dividend
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma Plc Earnings Call Summary for Q4/2025
- Royalty Pharma exceeded Q4 2025 forecasts with EPS of $1.47 (17.6% above expectations) and revenue of $874 million (9.78% above forecast), despite a slight premarket stock decline of 0.61%.
- The company achieved 16% growth in portfolio receipts for 2025, deployed $2.6 billion in capital, and returned $1.7 billion to shareholders through $1.2 billion in share repurchases and $500 million in dividends.
- For 2026, Royalty Pharma projects portfolio receipts between $3.275-$3.425 billion with royalty receipts growing 3-8%, and anticipates operational efficiencies to save $100 million.
- CEO Pablo Legorreta called 2025 'a landmark year,' highlighting the company's leadership in the biopharma royalty market and projecting 'strong low volatility, top and bottom-line growth through 2030 and beyond.'
- The company's development-stage pipeline has multiple pivotal readouts upcoming, with potential peak sales from these therapies estimated at $43 billion.
Last Updated: 2026-02-11, 09:22 a/m
Read Full TranscriptCompare RPRX to Peers and Sector
Metrics to compare | RPRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRPRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 28.6x | 11.7x | −0.4x | |
PEG Ratio | −4.19 | 0.01 | 0.00 | |
Price/Book | 4.5x | 3.0x | 2.6x | |
Price / LTM Sales | 12.4x | 2.1x | 3.2x | |
Upside (Analyst Target) | 2.7% | 33.9% | 46.7% | |
Fair Value Upside | Unlock | 20.9% | 7.6% | Unlock |
Analyst Ratings
8 Buy
2 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 52.44
(+5.84% Upside)
Earnings
Latest Release
Feb 11, 2026
EPS / Forecast
1.47 / 1.25
Revenue / Forecast
622M / 796.14M
People Also Watch
FAQ
What Is the Royalty Pharma (RPRX) Stock Price Today?
The Royalty Pharma stock price today is 49.55 USD.
What Stock Exchange Does Royalty Pharma Trade On?
Royalty Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Royalty Pharma?
The stock symbol for Royalty Pharma is "RPRX."
Does Royalty Pharma Pay Dividends? What’s The Current Dividend Yield?
The Royalty Pharma dividend yield is 1.89%.
What Is the Royalty Pharma Market Cap?
As of today, Royalty Pharma market cap is 29.31B USD.
What Is Royalty Pharma's Earnings Per Share (TTM)?
The Royalty Pharma EPS (TTM) is 1.78.
When Is the Next Royalty Pharma Earnings Date?
Royalty Pharma will release its next earnings report on May 06, 2026.
From a Technical Analysis Perspective, Is RPRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Royalty Pharma Stock Split?
Royalty Pharma has split 0 times.
How Many Employees Does Royalty Pharma Have?
Royalty Pharma has 100 employees.
What is the current trading status of Royalty Pharma (RPRX)?
As of Apr 24, 2026, Royalty Pharma (RPRX) is trading at a price of 49.55 USD, with a previous close of 49.64 USD. The stock has fluctuated within a day range of 49.20 USD to 49.64 USD, while its 52-week range spans from 31.84 USD to 50.08 USD.
What Is Royalty Pharma (RPRX) Price Target According to Analysts?
The average 12-month price target for Royalty Pharma is 52.44 USD, with a high estimate of 63 USD and a low estimate of 46 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +5.84% Upside potential.
What Is the RPRX Premarket Price?
RPRX's last pre-market stock price is 49.50 USD. The pre-market share volume is 30.00, and the stock has decreased by -0.14, or -0.28%.
What Is the RPRX After Hours Price?
RPRX's last after hours stock price is 49.65 USD, the stock has decreased by 0.01, or 0.02%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.